Reckitt Benckiser Group entered into acquisition agreement to acquire Adams Respiratory Therapeutics thus increasing its product portfolio with OTC and prescription pharmaceuticals for treating respiratory disorders, including Mucinex® expectorants (based on guaifenesin) and Delsym® (dextromethorphan polistirex) a cough suppressant. The acquisition deal would worth up to US$2.3 B to Adams.